Sign In
Buy HALO
$82.54
-0.760 (-0.91%)
At Close: Jul 31, 2026
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View
11:36am, Tuesday, 04'th Nov 2025
HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.
Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates
11:58pm, Monday, 03'rd Nov 2025
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.72 per share, beating the Zacks Consensus Estimate of $1.63 per share. This compares to earnings of $1.27 per share a year ago.
Halozyme Therapeutics, Inc. (HALO) Q3 2025 Earnings Call Transcript
08:16pm, Monday, 03'rd Nov 2025
Halozyme Therapeutics, Inc. ( HALO ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Tram Bui - Head of Investor Relations & Corporate Communications Helen Torley - President,
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
04:01pm, Monday, 03'rd Nov 2025
Royalty Revenue Increased 52% YOY to Record $236 million and Total Revenue Increased 22% YOY to Record $354 million Net Income Increased 28% YOY to $175 million; Adjusted EBITDA Increased 35% YOY to
Is Halozyme Stock a Portfolio Must-Have Ahead of Q3 Earnings?
01:45pm, Monday, 27'th Oct 2025
HALO gears up for third-quarter earnings with strong royalty growth and a new acquisition poised to shape its 2025 outlook.
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:06am, Monday, 27'th Oct 2025
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme Just Bought Its Next Decade Of Growth
01:17pm, Thursday, 23'rd Oct 2025
Halozyme's $750M Elektrofi acquisition expands its drug delivery leadership beyond ENHANZE into high-concentration biologic formulations. Elektrofi's Hypercon enables 400–500 mg/mL formulations for
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:51am, Tuesday, 21'st Oct 2025
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Halozyme to Report Third Quarter 2025 Financial and Operating Results
08:30am, Tuesday, 21'st Oct 2025
SAN DIEGO , Oct. 21, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2025 financial and operating results on Monday, Nove
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Monday, 20'th Oct 2025
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
10:41am, Friday, 17'th Oct 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme Rallies Almost 40% YTD: How Should You Play the Stock?
02:56pm, Thursday, 16'th Oct 2025
HALO's nearly 40% YTD surge is fueled by higher ENHANZE royalties. The Elektrofi deal also positions the company for long-term diversification.
Strong And Rising: Halozyme Therapeutics Stock May Have More Upside
08:35am, Friday, 10'th Oct 2025
Halozyme Therapeutics (HALO) stock could be a solid choice to leverage the current momentum. Why? Because it offers strong margins, a low-debt capital structure, reasonable valuation, and strong momen
Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth?
11:51am, Wednesday, 08'th Oct 2025
HALO's impending acquisition of Elektrofi will add Hypercon tech to broaden its drug delivery platform and support long-term growth.
Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript
03:22pm, Wednesday, 01'st Oct 2025
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) M&A Call October 1, 2025 8:30 AM EDT Company Participants Tram Bui - Head of Investor Relations & Corporate Communications Helen Torley - President, CEO & Di
